87 related articles for article (PubMed ID: 3582624)
1. [Biochemical characteristics of the anti-ischemic action of the new structural analog of gamma-butyrobetaine 3-(2,2,2,-trimethylhydrazine)propionate].
Simkhovich BZ; Meĭrena DV; Khagi KhB; Kalvin'sh IIa; Lukevits EIa
Farmakol Toksikol; 1987; 50(2):100-4. PubMed ID: 3582624
[TBL] [Abstract][Full Text] [Related]
2. [Effect of DL-carnitine and gamma-butyrobetaine hydroxylase inhibitor 3-(2,2,2-trimethylhydrazinium) propionate on isoproterenol-induced changes in the metabolism of the rat myocardium].
Simkhovich BZ; Meĭrena DV; Shutenko ZhV; Khagi KhB; Briede IaL
Vopr Med Khim; 1988; 34(5):30-4. PubMed ID: 3218133
[TBL] [Abstract][Full Text] [Related]
3. [The cardioprotective action of carnitine and its structural analog 3-(2,2,2-trimethylhydrazine)propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats].
Ratunova TM; Bauman VR; Kalvin'sh IIa
Farmakol Toksikol; 1989; 52(5):24-7. PubMed ID: 2599072
[TBL] [Abstract][Full Text] [Related]
4. [Effect of a new structural analog of gamma-butyrobetaine-- 3-(2,2,2-trimethylhydrazine)propionate (THP) on carnitine level, carnitine-dependent fatty acid oxidation and various indices of energy metabolism in the myocardium].
Simkhovich BZ; Meĭrena DV; Khagi KhB; Kalvin'sh IIa; Lukevits EIa
Vopr Med Khim; 1986; 32(4):72-6. PubMed ID: 3765501
[TBL] [Abstract][Full Text] [Related]
5. [The effect of a structural analog of gamma-butyrobetaine, mildronate, [3-2,2,2-trimethylhydrazine)propionate] on dynamic carnitine-dependent metabolism].
Shutenko ZhV; Priedena IA; Kalvin'sh IIa; Lukevits EIa
Vopr Med Khim; 1991; 37(3):24-6. PubMed ID: 1949676
[TBL] [Abstract][Full Text] [Related]
6. 3-(2,2,2-Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties.
Simkhovich BZ; Shutenko ZV; Meirena DV; Khagi KB; Mezapuķe RJ; Molodchina TN; Kalviņs IJ; Lukevics E
Biochem Pharmacol; 1988 Jan; 37(2):195-202. PubMed ID: 3342076
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level].
Simkhovich BZ; Vitolinia RO; Stivrinia MI; Shutenko ZhV; Meĭrena DV
Kardiologiia; 1987 Jul; 27(7):85-8. PubMed ID: 3656926
[TBL] [Abstract][Full Text] [Related]
8. [Regulation of carnitine-dependent metabolism of fatty acids in the rat myocardium using 3-(2,2,2-trimethylhydrazinium) propionate].
Shutenko ZhV; Simkhovich BZ; Meĭrena DV; Kalvin'sh IIa; Lukevits EIa
Vopr Med Khim; 1989; 35(2):59-64. PubMed ID: 2741413
[TBL] [Abstract][Full Text] [Related]
9. [Effect of the calcium antagonists ryodipine and verapamil on the carnitine-dependent metabolism of fatty acids in the rat heart].
Simkhovich BZ; Meĭrena DV; Khagi KhB; Shutenko ZhV; Mezhapuke RIa
Farmakol Toksikol; 1989; 52(1):34-7. PubMed ID: 2707416
[TBL] [Abstract][Full Text] [Related]
10. [Cardioprotective effect of carnitine and its synthetic analog 3-(2,2,2-trimethylhydrazinium) propionate in rats with experimental myocardial infarction].
Ianson TM; Bauman VR; Grom NP; Kienkas IA; Kalvin'sh IIa
Vopr Med Khim; 1988; 34(4):122-5. PubMed ID: 3195125
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts.
Kirimoto T; Nobori K; Asaka N; Muranaka Y; Tajima K; Miyake H
Arch Int Pharmacodyn Ther; 1996; 331(2):163-78. PubMed ID: 8937627
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on cardiac dysfunction induced by ischemia/reperfusion in isolated rat hearts.
Hayashi Y; Tajima K; Kirimoto T; Miyake H; Matsuura N
Pharmacology; 2000 Nov; 61(4):238-43. PubMed ID: 11093075
[TBL] [Abstract][Full Text] [Related]
13. [The effect of mildronate on disorders of the cardiac contractile function in rats caused by an excess of free fatty acids and ischemia].
Simkhovich BZ; Briede IaL; Ozola RA; Meĭrena DV; Kalvin'sh IIa; Lukevits EIa
Farmakol Toksikol; 1990; 53(5):27-9. PubMed ID: 2253743
[TBL] [Abstract][Full Text] [Related]
14. Biochemical derangements in ischemic myocardium: the role of carnitine.
Siliprandi N; Di Lisa F; Toninello A
G Ital Cardiol; 1984 Oct; 14(10):804-8. PubMed ID: 6240423
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney.
Kuwajima M; Harashima H; Hayashi M; Ise S; Sei M; Lu Km; Kiwada H; Sugiyama Y; Shima K
J Pharmacol Exp Ther; 1999 Apr; 289(1):93-102. PubMed ID: 10086992
[TBL] [Abstract][Full Text] [Related]
16. [Effect of doprostone on fatty acid metabolism disturbances in the rat heart caused by adrenergic influences].
Simkhovich BZ; Meĭrena DV; Khagi KhB; Freĭmanis IaF
Farmakol Toksikol; 1989; 52(4):24-7. PubMed ID: 2806522
[TBL] [Abstract][Full Text] [Related]
17. Effects of L-carnitine on tissue levels of free fatty acid, acyl CoA, and acylcarnitine in ischemic heart.
Suzuki Y; Kamikawa T; Kobayashi A; Yamazaki N
Adv Myocardiol; 1983; 4():549-57. PubMed ID: 6856980
[TBL] [Abstract][Full Text] [Related]
18. [The effect of the carnitine biosynthesis inhibitor mildronate on the lipid metabolic indices of rats].
Shutenko ZhV; Priedena IA; Mezhapuke RIa; Simkhovich BZ; Kalvin'sh IIa; Lukevits EIa
Farmakol Toksikol; 1991; 54(2):55-6. PubMed ID: 1884799
[TBL] [Abstract][Full Text] [Related]
19. [The effect of mildronate on carnitine-dependent and carnitine-independent ketogenesis in rats].
Simkhovich BZ; Meĭrena DV; Khagi KhB; Shutenko ZhV; Molodchina TN; Kalvin'sh IIa; Lukevits EIa
Farmakol Toksikol; 1991; 54(4):41-2. PubMed ID: 1786824
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.
Dambrova M; Makrecka-Kuka M; Vilskersts R; Makarova E; Kuka J; Liepinsh E
Pharmacol Res; 2016 Nov; 113(Pt B):771-780. PubMed ID: 26850121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
